The AJCC 8th Edition Breast Cancer Staging System specifies that the presence of ≥1 CTC per 7.5 mL in early-stage breast cancer patients indicates a poor prognosis. Domestic research teams have further validated that baseline and post-treatment CTC levels can predict outcomes in advanced breast cancer patients.